Warning for strontium supplement users

The European Medicines Agency's Committee for Medicinal Products for Human Use today recommended that the osteoporosis drug strontium ranelate no longer be used in immobilized patients or patients with venous thromboembolism. The committee also recommended updated warnings regarding serious skin reactions with strontium ranelate. It is not approved for the treatment of osteoporosis in the United States but is sold as a dietary supplement.